Clinical trial timelines are rarely lost during study conduct but are lost long before the first patient is screened. Delays in study startup often begin at country selection and feasibility where over‑optimistic assumptions, limited site insight, and fragmented planning quietly set the stage for downstream challenges.
At ProPharma, we approach study start‑up as an integrated, fit‑for‑purpose strategy and not a handoff between functions. From early country selection and feasibility through first patient in (FPI), our focus is on translating early insights into realistic timelines, aligned execution, and predictable activation across regions and sites.
Why Study Start‑Up So Often Slips
Country selection and feasibility are frequently treated as discrete activities: sites complete questionnaires, countries are selected, and timelines are modelled. In practice, this sequential approach often misses critical, localized signals:
- Site enthusiasm does not always align with site readiness
- Regulatory and ethics timelines vary significantly by region and country
- Contracting, budgets, and internal site processes are often underestimated
- Key risks surface after study award and project kick‑off, when options are already limited
The result is familiar: late‑stage changes, compressed timelines, and avoidable delays that impact both cost and confidence. This is rarely a failure of effort but a consequence of viewing study startup in silos rather than as a connected whole.
A Different Way to Think About Study Start‑Up
Effective study start-up is not driven by templates alone. It requires a deep understanding of regional and local realities and a structured, tight relationship between cross functional teams.
This means recognizing how regulatory pathways differ across countries, how sites truly operate day‑to‑day, and how local constraints influence readiness and sequencing. It also means relying on teams with boots‑on‑the‑ground experience, people who understand not just the rules, but how those rules are applied in practice.
At ProPharma, study startup is approached holistically. Our teams bring extensive local knowledge together within a connected global structure, enabling informed decisions early when they matter most.
This perspective shifts study startup from a series of tasks to a coordinated system of people, insight, and execution.
Turning Insight into Predictable Activation
What ultimately accelerates first patient in is not pressure but alignment between countries and sites, functions and individuals, assumptions and operational reality.
ProPharma’s study start‑up model is designed to maintain this alignment throughout execution by ensuring close collaboration across feasibility, startup, regulatory, and project delivery teams. Information does not stop at functional boundaries, and decisions are informed by those closest to the work.
This connectedness allows risks to surface earlier, dependencies to be understood more clearly, and expectations to remain realistic across the life of the study.
Why Predictability Matters More Than Aggressive Timelines
Sponsors do not simply need fast activation, but they need confidence. Over‑promising first patient in dates creates pressure, erodes trust, and often results in rework later.
Predictability is achieved when study startup reflects operational reality:
- aligned country strategies
- realistic site activation timelines
- fewer late‑stage changes that disrupt delivery
This creates a more stable foundation for study conduct and stronger working relationships with investigative sites.
A Proven Partner on the Study Journey
At ProPharma, study startup is not a transactional service but is a true partnership. Our structure enables clients to communicate directly with experienced team members and decision‑makers who remain engaged throughout the process.
By combining global reach with deep local expertise and a connected team model, we support clients as a trusted partner from feasibility through first patient in, and beyond.
If you are planning an upcoming study and want to reduce start‑up risk, improve predictability, and work with a team grounded in real‑world execution, we would welcome the conversation.
